[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy]

Area of Science:

• Pharmacology
• Endocrinology
• Oncology

Context:

• Selective Estrogen Receptor Modulators (SERMs) represent a class of compounds with tissue-specific estrogenic activity.
• Traditional hormone replacement therapy (HRT) has limitations due to potential risks to breast and endometrial tissues.
• Existing SERMs like tamoxifen have shown efficacy but carry risks such as increased endometrial cancer incidence.

Purpose:

• To evaluate the potential of SERMs, specifically raloxifene, as a safer alternative for postmenopausal hormone replacement.
• To assess the efficacy of raloxifene in managing bone mineral density (BMD) and fracture risk in postmenopausal women.
• To compare the safety profile of raloxifene with existing treatments for osteoporosis and breast cancer prevention.

Summary:

• SERMs act as estrogen agonists in some tissues and antagonists in others, offering a potentially ideal profile for postmenopausal treatment.
• Raloxifene demonstrates efficacy in preventing postmenopausal bone loss and reducing vertebral fracture incidence by approximately 50%.
• Unlike tamoxifen, raloxifene does not stimulate endometrial or mammary tissue, and may even lower breast cancer risk, though it carries risks of thromboembolism and leg cramps similar to HRT.

Impact:

• Raloxifene presents a viable option for the prevention and treatment of postmenopausal osteoporosis in women without climacteric symptoms.
• Its use can be combined with other osteoporosis treatments like calcium, vitamin D, bisphosphonates, and calcitonin.
• Future applications may extend to the management of male osteoporosis.